Abstract Details

Title Phase 2B Randomized Dose-Ranging Clinical Trial of Tamoxifen, a Non-Steroidal Tri-Phenyl-Ethylene Selective Estrogen Receptor Modulator [SERM], in Amyotrophic Lateral Sclerosis[ALS]: Increased Survival in 20-30-40mg Daily Compared with 10mg Weekly-10mg Daily Treatment Cohorts

Topic Anterior Horn and Peripheral Nerve

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Afraa M. Musa (Faculty of Medicine Univeristy of)	No disclosure on file
Ammar Ahmed, MBBS, PhD, FRCP, Lond (S.U.Hospital F.of M .U.ofK.plus UMST. Plus NMT S.A for short mission)	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��